Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HER2 Positive Metastatic Breast Cancers”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05018702
What this trial is testing

ARX788 in HER2-positive Breast Cancer Patients With Brain Metastases

Who this might be right for
HER2-positive, Metastatic Breast Cancer
Fudan University 32
Testing effectiveness (Phase 2)UnknownNCT01730677
What this trial is testing

Lapatinib+Vinorelbine vs Vinorelbine HER2 Positive Metastatic Breast Cancer Progressed After Lapatinib/Trastuzumab

Who this might be right for
Metastatic Breast Cancer
National Cancer Center, Korea 150
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07336771
What this trial is testing

JSKN016 in Combination With D-0502 for Locally Advanced or Metastatic HR-Positive, HER2-Negative Breast Cancer

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer (LABC)
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 60
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07179939
What this trial is testing

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Who this might be right for
HER2-positive Breast Cancer
Fudan University 288
Not applicableStudy completedNCT05155566
What this trial is testing

Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.

Who this might be right for
Breast Cancer Metastatic
Pfizer 847
Testing effectiveness (Phase 2)Looking for participantsNCT06110793
What this trial is testing

Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center 56
Testing effectiveness (Phase 2)Study completedNCT00387907
What this trial is testing

Study of Larotaxel in Combination With Weekly Herceptin® in Patients With HER2 Positive Metastatic Breast Cancer

Who this might be right for
Advanced Breast CancerBreast CancerMetastatic Breast Cancer
Sanofi 6
Large-scale testing (Phase 3)Study completedNCT00630032
What this trial is testing

Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer

Who this might be right for
Breast Cancer
UNICANCER 762
Large-scale testing (Phase 3)UnknownNCT04385563
What this trial is testing

Evaluate the Efficacy and Safety of the Combination of TQ-B211 Plus Docetaxel in Patients With HER2-positive MBC.

Who this might be right for
HER2-positive Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 338
Testing effectiveness (Phase 2)UnknownNCT04165993
What this trial is testing

Study of KN026 Monotherapy or Combination Therapy in Patients With Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Jiangsu Alphamab Biopharmaceuticals Co., Ltd 68
Early research (Phase 1)Study completedNCT05759949
What this trial is testing

First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid Tumors

Who this might be right for
PIK3CA MutationSolid Tumor, AdultHER2-negative Breast Cancer+5 more
Relay Therapeutics, Inc. 41
Testing effectiveness (Phase 2)Study completedNCT03054363
What this trial is testing

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

Who this might be right for
Breast Cancer
University of Colorado, Denver 42
Testing effectiveness (Phase 2)Looking for participantsNCT06179303
What this trial is testing

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Locally Advanced Unresectable HER2-Negative Breast Carcinoma+3 more
University of Washington 60
Testing effectiveness (Phase 2)UnknownNCT04293276
What this trial is testing

Study to Evaluate the Efficacy and Safety of SHR6390 Combined With Pyrotinib in HER2+ Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Henan Cancer Hospital 41
Early research (Phase 1)WithdrawnNCT04498520
What this trial is testing

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8Anatomic Stage IIIB Breast Cancer AJCC v8+32 more
Pamela Munster
Not applicableStudy completedNCT05253911
What this trial is testing

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens.

Who this might be right for
HER2-positive Breast Cancer
iOMEDICO AG 49
Early research (Phase 1)Temporarily pausedNCT05378464
What this trial is testing

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Who this might be right for
HER2-positive Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute 28
Testing effectiveness (Phase 2)Study completedNCT00444587
What this trial is testing

Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Hoffmann-La Roche 114
Not applicableLooking for participantsNCT03723928
What this trial is testing

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Estrogen Receptor PositiveHER2/Neu Negative+3 more
SWOG Cancer Research Network 739
Testing effectiveness (Phase 2)Ended earlyNCT00427427
What this trial is testing

Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center 75
Next Page